月度归档：2024年10月

上海衡平数字粘度计NDJ-5S

发表于由

上海衡平数字粘度计NDJ-5S

  • 品牌 衡平|CNSHP
  • 型号 NDJ-5S
  • 商品详情

    产品简介：

        NDJ-5S型液晶显示粘度计是本厂旋转粘度计的升级换代产品。本仪器采用机械设计、制造工艺和微电脑控制技术，数据采集正确；显示器选用蓝背光、高亮度的LED显示屏，数据显示清晰。

        本仪器具有测量灵敏度高，测试结果可靠，使用操作方便，造型美观大方等特点，是用来测量牛顿液体的绝对粘度和非牛顿液体的表观粘度的理想仪器，可广泛应用于油脂、油漆、塑料、药物、食品、涂料、洗涤剂等各种流体粘度的测量。

        本仪器还配有RS-232、温度传感器、打印机等接口功能。选配与PC机连接线并安装光盘后，可按需记录各项测试数据；选配温度传感器可实测液体的温度；选配微型打印机可直接打印测试结果。

     

    产品特点：

    全铝机头，屏蔽性能优越；
    NDJ-5S选配有电脑连接软件光盘
    高亮度LCD显示；
    配有RS-232通讯接口可连接PC；
    选配温度传感器，可实测液体温度；
    选配微型打印机可直接打印测试结果。

     

    技术参数：

    型号 NDJ-5S
    测量范围 1～1×105mPa.s
    转子规格 标配1-4号转子   （选配0号转子可测低粘度至0.1~10mPa.s）
    转子转速（转/分）  6、12、30、60  （转/分）
     自动挡 能自动选择合适的转子号和转速 
     操作选择 中/英文 
    单次测量自动停止 测量结果稳定后，转子自动停止
    测量精度 ±2%（牛顿液体）
    供电电源 交流220V±10%   50HZ±10%
    工作环境 温度5℃~35℃，相对湿度不大于80%
    外形尺寸(mm) 380×320×390   
    净重(kg) 4.5

    • 茴香霉素，来自灰色链霉菌的现成溶液

    发表于由

    茴香霉素，来自灰色链霉菌的现成溶液

    10mg/mL in DMSO

    有货

    茴香霉素，来自灰色链霉菌的现成溶液

    CAS编号 22862-76-6 | 品牌：Jinpan
    Anisomycin, Ready Made Solution from Streptomyces griseolus

    MSDS

    质检证书(CoA)

    相似产品

    • 分子式 C14H19NO4
    • 分子量265.3
    • Beilstein号 20705
    • EC号 245-269-7
    • PubChem编号 253602

    货号 (SKU) 包装规格 是否现货 价格 数量
    A466191-0.5ml 0.5ml 期货 茴香霉素，来自灰色链霉菌的现成溶液  

    基本信息

    产品名称 茴香霉素，来自灰色链霉菌的现成溶液
    英文名称 Anisomycin, Ready Made Solution from Streptomyces griseolus
    英文别名 Flagecidin, 2-[(4-Methoxyphenyl)methyl]-3,4-pyrrolidinediol 3-acetate, (2R,3S,4S)-2-(4-Methoxybenzyl)-3,4-pyrrolidinediol-3-acetate
    规格或纯度 10mg/mL in DMSO
    运输条件 超低温冰袋运输

    相关属性

    CAS编号 22862-76-6
    比旋光度 -30° (C=1,MeOH)
    熔点 144 °C
    储存温度 -20°C储存
    RTECS BZ9800000
    分子量 265.3
    分子式 C14H19NO4
    EC号 245-269-7
    品牌 Jinpan
    PubChem CID 253602

    BFCAs-1

    发表于由

    上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

    BFCAs-1 

    BFCAs-1是一种双功能螯合剂，在医学影像和生物化学中常用。

    BFCAs-1

    BFCAs-1 Chemical Structure

    CAS No. : 585531-74-4

    规格 是否有货
    100 mg   询价  
    250 mg   询价  
    500 mg   询价  

    * Please select Quantity before adding items.

    生物活性

    BFCAs-1 is a polyamino polycarboxylic bifunctional chelating agent(BFCAs); a broad range of applications in chemistry, biology and medicine and diagnostic imaging (MRI, SPECT, PET).

    分子量

    628.84

    Formula

    C32H60N4O8
    CAS 号

    585531-74-4
    运输条件

    Room temperature in continental US; may vary elsewhere.
    储存方式

    Please store the product under the recommended conditions in the Certificate of Analysis.
    参考文献

    • [1]. Lattuada L, et al. The synthesis and application of polyamino polycarboxylic bifunctional chelating agents. Chem Soc Rev. 2011 May;40(5):3019-49.

      [2]. Keliris A, et al. Synthesis and characterization of a cell-permeable bimodal contrast agent targeting β-galactosidase. Bioorg Med Chem. 2011 Apr 15;19(8):2529-40.

    所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

    Dexmedetomidine-13C,d3 hydrochloride(Synonyms: (+)-Medetomidine-13C,d3 hydrochloride; (S)-Medetomidine-13C,d3 hydrochloride)

    发表于由

    上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

    Dexmedetomidine-13C,d3 hydrochloride (Synonyms: (+)-Medetomidine-13C,d3 hydrochloride; (S)-Medetomidine-13C,d3 hydrochloride)

    Dexmedetomidine-13C,d3 (hydrochloride) 是一种 13C- 和氘代标记的 Dexmedetomidine (hydrochloride)。Dexmedetomidine hydrochloride ((+)-Medetomidine hydrochloride) 是一种有效，选择性和具有口服活性的 α2 肾上腺素能受体 (α2-adrenoceptor) 激动剂，Ki 值为 1.08 nM。Dexmedetomidine hydrochloride 对 α1 肾上腺素受体显示出 1620 倍的选择性。Dexmedetomidine hydrochloride 具有抗焦虑作用，可用于促进安定和缓解疼痛的研究。

    Dexmedetomidine-13C,d3 hydrochloride(Synonyms: (+)-Medetomidine-13C,d3 hydrochloride; (S)-Medetomidine-13C,d3 hydrochloride)

    Dexmedetomidine-13C,d3 hydrochloride Chemical Structure

    规格 是否有货
    100 mg   询价  
    250 mg   询价  
    500 mg   询价  

    * Please select Quantity before adding items.

    生物活性

    Dexmedetomidine-13C,d3 (hydrochloride) is the 13C- and deuterium labeled. Dexmedetomidine hydrochloride ((+)-Medetomidine hydrochloride) is a potent, selective and orally active agonist of α2-adrenoceptor, with a Ki of 1.08 nM. Dexmedetomidine hydrochloride shows 1620-fold selectivity against α1-adrenoceptor. Dexmedetomidine hydrochloride exhibits anxiolysis, sedation, and modest analgesia effects[1][2][3].

    体外研究
    (In Vitro)

    Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[78].

    Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
    分子量

    240.75

    Formula

    C1213CH14D3ClN2
    运输条件

    Room temperature in continental US; may vary elsewhere.
    储存方式

    Please store the product under the recommended conditions in the Certificate of Analysis.
    参考文献

    • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223.

      [2]. Virtanen R, et, al. Characterization of the selectivity, specificity and potency of medetomidine as an alpha 2-adrenoceptor agonist. Eur J Pharmacol. 1988 May 20;150(1-2):9-14.

      [3]. Gertler R, et, al. Dexmedetomidine: a novel sedative-analgesic agent. Proc (Bayl Univ Med Cent). 2001 Jan;14(1):13-21.

      [4]. Sajid B, et, al. A comparison of oral dexmedetomidine and oral midazolam as premedicants in children. J Anaesthesiol Clin Pharmacol. Jan-Mar 2019;35(1):36-40.

    所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

    ZM39923

    发表于由

    上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

    ZM39923 

    ZM39923 是一种 JAK3 抑制剂， pIC50 值为 7.1；ZM39923 同时可抑制组织型转谷氨酞胺酶 (TGM2) 的活性，IC50 值为 10 nM。

    ZM39923

    ZM39923 Chemical Structure

    CAS No. : 273727-89-2

    规格 是否有货
    100 mg   询价  
    250 mg   询价  
    500 mg   询价  

    * Please select Quantity before adding items.

    ZM39923 的其他形式现货产品:

    ZM39923 hydrochloride

    生物活性

    ZM39923 is a JAK3 inhibitor, with a pIC50 of 7.1; ZM39923 also potently inhibits tissue transglutaminase (TGM2) with an IC50 of 10 nM.

    IC50 & Target[1][2]

    JAK3

    7.1 (pIC50)

    JAK1

    4.4 (pIC50)

    EGF-R

    5.6 (pIC50)

    Lck

    5.0 (pIC50)

    CDK4

    5.0 (pIC50)

    TGM2

    10 nM (IC50)

    体外研究
    (In Vitro)

    ZM39923 is a JAK3 inhibitor, with a pIC50 of 7.1. ZM39923 (Compound 7) shows weak inhibitory effect on EGF-R and JAK1 (pIC50, 5.6, 4.4, respectively), and insignificantly inhibits tyrosine kinases Lck and CDK4 (pIC50 <5.0)[1]. ZM39923 potently inhibits tissue transglutaminase (TGM2) with an IC50 of 10 nM, and acts directly on purified TGM2 to inhibit the Ca2+ activated form of TGM2[2]. ZM39923 blocks the phosphorylation of JAK3 induced by CCL19, and such an effect is similar to that of CCR7 antibody. ZM39923 also significantly blocks the CCL19 induced wound closure rate, and decreases the migration and invasion of PCI-37B cells[3].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
    分子量

    331.45

    Formula

    C23H25NO
    CAS 号

    273727-89-2
    运输条件

    Room temperature in continental US; may vary elsewhere.
    储存方式

    Please store the product under the recommended conditions in the Certificate of Analysis.
    参考文献

    • [1]. Brown GR, et al. Naphthyl ketones: a new class of Janus kinase 3 inhibitors. Bioorg Med Chem Lett. 2000 Mar 20;10(6):575-9.

      [2]. Lai TS, et al. Identification of chemical inhibitors to human tissue transglutaminase by screening existing drug libraries. Chem Biol. 2008 Sep 22;15(9):969-78.

      [3]. Zhang Z, et al. Jak3 is involved in CCR7-dependent migration and invasion in metastatic squamous cell carcinoma of the head and neck. Oncol Lett. 2017 May;13(5):3191-3197.

    Cell Assay
    [3]

    PCI-37B (a metastatic SCCHN cell line expressing CCR7) cells are cultured in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum, penicillin, and streptomycin in an atmosphere of 5% CO2 and 95% air at 37°C. The ZM39923 inhibitor treatment at the dose determined using the Cell Counting Kit-8[3].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
    参考文献

    • [1]. Brown GR, et al. Naphthyl ketones: a new class of Janus kinase 3 inhibitors. Bioorg Med Chem Lett. 2000 Mar 20;10(6):575-9.

      [2]. Lai TS, et al. Identification of chemical inhibitors to human tissue transglutaminase by screening existing drug libraries. Chem Biol. 2008 Sep 22;15(9):969-78.

      [3]. Zhang Z, et al. Jak3 is involved in CCR7-dependent migration and invasion in metastatic squamous cell carcinoma of the head and neck. Oncol Lett. 2017 May;13(5):3191-3197.

    所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

    Ensartinib(Synonyms: X-396)

    发表于由

    上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

    Ensartinib (Synonyms: X-396)

    Ensartinib (X-396) 是一种有效的双重的 ALK/MET 抑制剂，IC50 分别 <0.4 nM 和 0.74 nM。

    Ensartinib(Synonyms: X-396)

    Ensartinib Chemical Structure

    CAS No. : 1370651-20-9

    规格 是否有货
    100 mg   询价  
    250 mg   询价  
    500 mg   询价  

    * Please select Quantity before adding items.

    Ensartinib 的其他形式现货产品:

    Ensartinib dihydrochloride

    生物活性

    Ensartinib (X-396) is a potent and dual ALK/MET inhibitor with IC50s of <0.4 nM and 0.74 nM, respectively.

    IC50 & Target[1]

    MET

    0.74 nM (IC50)

    体外研究
    (In Vitro)

    The ability of Ensartinib (X-396) to inhibit the growth of different cancer cell lines harboring ALK fusions or point mutations is tested. Ensartinib is potent in H3122 lung cancer cells harboring EML4-ALK E13;A20 (IC50: 15nM). Ensartinib is also potent in H2228 lung cancer cells harboring EML4-ALK E6a/b; A20 (IC50: 45 nM). Furthermore, X-376 is potent in SUDHL-1 lymphoma cells harboring NPM-ALK (IC50: 9 nM). X-376 also inhibits SY5Y neuroblastoma cells harboring ALK F1174L, MKN-45 gastric carcinoma cells harboring MET dependent, HepG2 cells and PC-9 lung cancer cell lines harboring EGFR exon 19 del with IC50s of 68 nM, 156 nM, 9.644 μM and 2.989 μM, respectively[1].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
    体内研究
    (In Vivo)

    The effects of Ensartinib (X-396) in vivo against H3122 xenografts are examined. A pharmacokinetic study reveals that Ensartinib shows substantial bioavailability and moderate half-lives in vivo. Nude mice harboring H3122 xenografts are treated with Ensartinib at 25mg/kg bid. Ensartinib significantly delays the growth of tumors compared to vehicle alone. In the xenograft experiments, Ensartinib appears well-tolerated in vivo. Mouse weight is unaffected by Ensartinib treatment. Drug-treated mice appear healthy and do not display any signs of compound related toxicity. To further assess potential side effects of Ensartinib, additional systemic toxicity and toxico-kinetic studies are performed in Sprague Dawley (SD) rats. Following 10 days of repeated oral administration of Ensartinib at 20, 40, 80 mg/kg in SD rats, all animals survive to study termination. The no significant toxicity (NST) levels are determined to be 80mg/kg for Ensartinib. At NST levels, Ensartinib achieves an AUC of 66 μM×hr and a Cmax of 7.19 μM[1].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial

    分子量

    561.44

    Formula

    C26H27Cl2FN6O3
    CAS 号

    1370651-20-9
    中文名称

    爱沙替尼
    运输条件

    Room temperature in continental US; may vary elsewhere.
    储存方式

    Please store the product under the recommended conditions in the Certificate of Analysis.
    参考文献

    • [1]. Lovly CM, et al. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinaseinhibitors. Cancer Res. 2011 Jul 15;71(14):4920-31.
    Cell Assay
    [1]

    For viability experiments, cells are seeded in 96-well plates at 25%-33% confluency and exposed to drugs.The human lung adenocarcinoma cell lines H3122 and H2228 are treated with Ensartinib (10, 30, 100, 300 and 1000 nM). SUDHL-1 lymphoma cells are treated with Ensartinib (5, 10, 30, 100 and 300 nM). SY5Y neuroblastoma cells are treated with Ensartinib (30, 100, 300 and 1000 nM). At 72 hours post Ensartinib addition, Cell Titer Blue Reagent is added and fluorescence is measured on a Spectramax spectrophotometer. All experimental points are set up in hextuplicate replicates and are performed at least two independent times. IC50s are calculated using GraphPad Prism version 5 for Windows. The curves are fit using a nonlinear regression model with a log (inhibitor) vs. response formula[1].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
    Animal Administration
    [1]

    Mice[1]
    Nude mice (nu/nu) are injected with H3122 cells. Once tumors reach an average volume of 450 mm3, a total of 27 athymic mice harboring H3122 tumors are randomized and dosed via oral gavage with 25mg/kg Ensartinib (X-396) or the control vehicle. Two, five, and fifteen hours after the single treatment (3 tumors/timepoint/group), mice are sacrificed and serum is collected for assessment of drug concentration using an LC-MS based bioanalytical method.

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
    参考文献

    • [1]. Lovly CM, et al. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinaseinhibitors. Cancer Res. 2011 Jul 15;71(14):4920-31.

    所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

    多肽定制Z-DEVD-CMK 编码 [250584-13-5]

    发表于由

    上海金畔生物科技有限公司可以定制不同序列多肽，可以访问官网了解更多产品信息。

    名称 Z-DEVD-CMK
    编码 [250584-13-5]
    别名 Z-DEVD-CMK
    纯度 80%，90%，95%，98%，99%
    重量 1mg,5mg,10mg,50mg,100mg,1g
    序列（单字母缩写） Z-DEVD-CMK
    序列（三字母缩写） Z-Asp-Glu-Val-Asp-CMK
    基本描述 Fluorogenic substrate that corresponds to one of the cleavage sites of the inactive 32 kD caspase-3 precursor (amino acids 172-175). Substrate for granzyme B.
    溶解度
    分子量 643
    化学式 C27H35Cl1N4O12
    存储条件 Store at -20°C. Keep tightly closed. Store in a cool dry place.
    注释
    Documents Z-DEVD-CMK 编码 [250584-13-5]
    Figures Z-DEVD-CMK 编码 [250584-13-5]
    Reference R. Sch?fer et al., Exp. Cell Res. , 240, 28 (1998) S. Bourteele et al., J. Biol. Chem., 273, 13245 (1998)
    C端
    N端
    化学桥

    GDC-0927 Racemate(Synonyms: SRN-927 Racemate)

    发表于由

    上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

    GDC-0927 Racemate (Synonyms: SRN-927 Racemate)

    GDC-0927 Racemate (SRN-927 Racemate) 是雌激素受体 (estrogen receptor) 的降解剂，能够有效抑制 ER-α 的活性，IC50 值为 0.2 nM，可用于雌激素受体有关的疾病。

    GDC-0927 Racemate(Synonyms: SRN-927 Racemate)

    GDC-0927 Racemate Chemical Structure

    CAS No. : 1443983-36-5

    规格 是否有货
    100 mg   询价  
    250 mg   询价  
    500 mg   询价  

    * Please select Quantity before adding items.

    生物活性

    GDC-0927 Racemate (SRN-927 Racemate) is a degrader of estrogen receptor, potently inhibits ER-α activity, with an IC50 of 0.2 nM, and is used in the research of ER-related diseases.

    IC50 & Target

    IC50: 0.2 nM (ER-α)[1]
    体外研究
    (In Vitro)

    GDC-0927 Racemate (Example 1) is a degrader of estrogen receptor, potently inhibits ER-α activity, with an IC50 of 0.2 nM, and is used in the research of ER-related diseases. GDC-0927 Racemate reduces the viability of MCF7 cells with an IC50 of 0.21 nM[1].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
    分子量

    461.52

    Formula

    C28H28FNO4
    CAS 号

    1443983-36-5
    运输条件

    Room temperature in continental US; may vary elsewhere.
    储存方式

    Please store the product under the recommended conditions in the Certificate of Analysis.
    参考文献

    • [1]. Mehmet Kahraman, et al. Estrogen receptor modulator and uses thereof. WO2014205138A1.

    所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

    EGFR-IN-2

    发表于由

    上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

    EGFR-IN-2 

    EGFR-IN-2 是一种非共价的，不可逆的，突变选择性的二代 EGFR 抑制剂。

    EGFR-IN-2

    EGFR-IN-2 Chemical Structure

    CAS No. : 1643497-70-4

    规格 是否有货
    100 mg   询价  
    250 mg   询价  
    500 mg   询价  

    * Please select Quantity before adding items.

    生物活性

    EGFR-IN-2 is a a noncovalent, irreversible, mutant-selective second generation EGFR inhibitor.

    IC50 & Target

    EGFR[1]
    体外研究
    (In Vitro)

    EGFR-IN-2 (Compound 21) inhibits EGFR autophosphorylation with IC50s of 0.027 μM, 0.009 μM ,0.033 μM , and 0.218 μM in double mutant TMLR cell line H1975, double mutant TMdel cell line PC9-ER, activating mutant del cell line PC9, and wild type cell line H292. In addition, EGFR-IN-2 demonstrats strong antiproliferative effect on the T790M mutant carrying H1975 cell line (IC50=0.361 μM) and the single activating mutant PC9 cell line (IC50=0.151 μM). Furthermore, EGFR-IN-2 also shows good selectivity against other kinases when evaluated in a 225-kinase panel (12/225 kinases inhibited at >70% when tested at 0.1 μM, 61-fold over the TMLR Ki and 63-fold over the TMdel Ki)[1].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
    体内研究
    (In Vivo)

    To examine its inhibitory effect on pEGFR levels in vivo, EGFR-IN-2 (Compound 21) is studied in a mouse H1975 (TMLR) xenograft model. After a single oral dose of 21 at 50 mg/kg, free plasma concentrations of EGFR-IN-2 at or exceeding the in vitro p-EGFR IC50 of 0.027 μM are sustained over 8 h. When administered at 100 mg/kg, the coverage of p-EGFR IC50 is extended to the last measured time point of 16 h postdose. Corresponding knockdown of p-EGFR and the downstream effectors pERK1/2 and AKT levels are observed at those time points, suggesting target engagement in vivo. In mouse, after intravenous and oral administration, the plasma clearance of EGFR-IN-2 is determined to be 104 mL/kg per min with a bioavailability of 19%. In dogs, the plasma clearance is 13 mL/kg per min with an oral bioavailability of 30%[1].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
    分子量

    551.66

    Formula

    C26H33N9O3S
    CAS 号

    1643497-70-4
    运输条件

    Room temperature in continental US; may vary elsewhere.
    储存方式

    Please store the product under the recommended conditions in the Certificate of Analysis.
    参考文献

    • [1]. Chan BK, et al. Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor. J Med Chem. 2016 Oct 13;59(19):9080-9093.
    Animal Administration
    [1]

    Mice[1]
    Eight week old female SCID beige mice are inoculated subcutaneously with 5×106 NCI-H1975 cells. When tumors reach a mean volume of 300 to 500 mm3, mice with similarly sized tumors are randomized into treatment groups. EGFR-IN-2 at 50 mg/kg or 100 mg/kg is administered orally as a single dose. Tumor and plasma samples are collected at 2, 8 or 16 h post dose[1].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
    参考文献

    • [1]. Chan BK, et al. Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor. J Med Chem. 2016 Oct 13;59(19):9080-9093.

    所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

    上海衡平数字粘度计NDJ-4S

    发表于由

    上海衡平数字粘度计NDJ-4S

  • 品牌 衡平|CNSHP
  • 型号 NDJ-4S
  • 商品详情

    产品特点：

    • 取代指针式旋转粘度计

    • 高亮度LED数码管显示

    • 一键选配转子号

    • 一键调整转速

    • 一键读取粘度值

    • 精致铝壳包装

     

    产品简介：

    NDJ-4s数显旋转粘度计是传统指针式旋转粘度计的升级换代产品。本仪器采用机械设计、制造工艺和单片机控制技术，LED 数码管显示，测量准确；本粘度计采用简洁的三个按键操作模式，一键选配转子号，一键调整转速，一键读取粘度值，使用极为方便。

    NDJ-1S(4S)型数字显示粘度计具有测量灵敏度高，测试结果可靠，使用操作方便，造型美观大方等特点，是用来测量牛顿液体的绝对粘度和非牛顿液体的表观粘度的理想仪器，可广泛应用于油脂、油漆、塑料、药物、食品、涂料、洗涤剂等各种流体粘度的测量。

    技术参数：

    型号 NDJ-4S
    测量范围 1～2×106mPa.s
    转子规格 标配1-4号转子   （选配0号转子可测低粘度至0.1~10mPa.s）
    转子转速（转/分） 0.3、0.6、1.5、3、6、12、30、60 
    单次测量自动停止 测量结果稳定后，转子自动停止
    测量精度 ±2%（牛顿液体）
    供电电源 交流220V±10%   50HZ±10%
    工作环境 温度5℃~35℃，相对湿度不大于80%
    外形尺寸(mm) 380×320×390   
    净重(kg) 4.5

    • c-Met-IN-2

    发表于由

    上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

    c-Met-IN-2 

    c-Met-IN-2 是一种有效的，选择性的，可口服的 c-Met 抑制剂，IC50 值为 0.6 nM，具有抗肿瘤活性。

    c-Met-IN-2

    c-Met-IN-2 Chemical Structure

    CAS No. : 1635406-73-3

    规格 是否有货
    100 mg   询价  
    250 mg   询价  
    500 mg   询价  

    * Please select Quantity before adding items.

    生物活性

    c-Met-IN-2 is a potent, selective and orally available c-Met inhibitor, with an IC50 of 0.6 nM, with antitumor activity.

    IC50 & Target

    IC50: 0.6 nM (c-Met)[1]
    体外研究
    (In Vitro)

    c-Met-IN-2 (Compound 14) is a potent and selective c-Met inhibitor, with an IC50 of 0.6 nM. c-Met-IN-2 also shows weak activity on other kinases, with IC50s of 1075 nM (AxI), 731 nM (RON), 18364 nM (VEGFR2), 5396 nM (c-Kit), 2357 nM (PDGFRa), 17056 nM (c-Src).

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
    体内研究
    (In Vivo)

    c-Met-IN-2 (0.1, 1, 10 mg/kg, p.o., once daily) significantly reduces the volume of tumor in mice bearing H1993 tumors, and has similar effect in SNU-5 xenograft model via oral administration at 0.3, 1 and 3 mg/kg[1].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
    分子量

    484.49

    Formula

    C24H21FN10O
    CAS 号

    1635406-73-3
    运输条件

    Room temperature in continental US; may vary elsewhere.
    储存方式

    Please store the product under the recommended conditions in the Certificate of Analysis.
    参考文献

    • [1]. Zhao F, et al. Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization. Eur J Med Chem. 2017 Jul 7;134:147-158.
    Cell Assay
    [1]

    NCI-H1993 cell line and SNU-5 cell line are maintained in RPMI 1640 media and supplemented with 10% fetal bovine serum. NCI-H1993 cells are seeded at 5000 cells/well in 96-well plates and incubated overnight. On the next day, the cells are exposed to various concentrations of c-Met-IN-2 and further cultured for 72 h. After chromogenic reaction with CCK-8, the OD450 (with reference of OD650) is measured using a Flexstation 3 reader. IC50 values are calculated using the GraphPad Prism Software. Each experiment is carried out thrice, each time in duplicate. The SNU-5 cell line assay is operated in a similar procedure as NCI-H1993 assay[1].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
    Animal Administration
    [1]

    Mice[1]
    The SNU-5 at a density of 6 × 106 tumor cells in 200 μL or NCI-H1993 at a density of 7 × 106 tumor cells in 140 μL are injected s. c. into the right flank of nude mice. Tumor-bearing animals are sorted into groups with similar mean tumor volumes prior to treatment (usually 100-200 mm3 for SNU-5 and 150-250 mm3 for NCI-H1993). The mice are randomly assigned into control and treatment groups (n = 7 (NCI-H1993 model) or n = 6 (SNU-5 model) per group). Control groups are given vehicle alone, and treatment groups receive c-Met-IN-2 as indicated doses via oral administration once daily for 2 weeks in SNU-5 model and oral administration once daily for 3 weeks in NCI-H1993 model, respectively. The sizes of the tumors are measured twice per week using a caliper, and the tumor volume is calculated in cubic millimeter using the formula: V = (A × B2)/2, where A and B is the long and short diameters of the tumor, respectively. Body weights are monitored throughout the study as a gross measure of toxicity/morbidity. Tumor growth inhibition (TGI), expressed in percent (%), is calculated using the formula: 100% × (1-((treatedfinal day-treatedday 0)/(controlfinal day-controlday 0))). Percent tumor regression (PTR), expressed in percent (%), is calculated using the formula: 100% × (treatedday 0-treatedfinal day)/treatedday 0[1].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
    参考文献

    • [1]. Zhao F, et al. Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization. Eur J Med Chem. 2017 Jul 7;134:147-158.

    所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

    PD-1-IN-17 TFA

    发表于由

    上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

    PD-1-IN-17 TFA 

    PD-1-IN-17 TFA 是一种有效的程序性细胞死亡-1 (PD-1) 抑制剂，详细信息请参考专利文献 WO2015033301A1 中的化合物 12，浓度为 100 nM 时抑制 92% 脾细胞增殖。

    PD-1-IN-17 TFA

    PD-1-IN-17 TFA Chemical Structure

    规格 是否有货
    100 mg   询价  
    250 mg   询价  
    500 mg   询价  

    * Please select Quantity before adding items.

    PD-1-IN-17 TFA 的其他形式现货产品:

    PD-1-IN-17

    生物活性

    PD-1-IN-17 TFA is a programmed cell death-1 (PD-1) inhibitor extracted from patent WO2015033301A1, Compound 12, inhibits 92% splenocyte proliferation at 100 nM[1].

    IC50 & Target

    PD-1[1]
    分子量

    488.37

    Formula

    C15H23F3N6O9
    运输条件

    Room temperature in continental US; may vary elsewhere.
    储存方式

    Please store the product under the recommended conditions in the Certificate of Analysis.
    参考文献

    • [1]. Pottayil Govindan Nair Sasikumar, et al. 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators. WO2015033301A1.

    所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

    BGT226(Synonyms: NVP-BGT226)

    发表于由

    上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

    BGT226 (Synonyms: NVP-BGT226)

    BGT226 (NVP-BGT226) 是一种 PI3K (针对 PI3Kα，PI3Kβ，PI3Kγ 的 IC50分别是4 nM，63 nM，38 nM ) /mTOR 双抑制剂，对人头颈癌细胞具有较强的生长抑制活性。

    BGT226(Synonyms: NVP-BGT226)

    BGT226 Chemical Structure

    CAS No. : 915020-55-2

    规格 是否有货
    100 mg   询价  
    250 mg   询价  
    500 mg   询价  

    * Please select Quantity before adding items.

    BGT226 的其他形式现货产品:

    BGT226 maleate

    生物活性

    BGT226 (NVP-BGT226) is a PI3K (with IC50s of 4 nM, 63 nM and 38 nM for PI3Kα, PI3Kβ and PI3Kγ)/mTOR dual inhibitor which displays potent growth-inhibitory activity against human head and neck cancer cells[1][2].

    IC50 & Target[1]

    PI3Kα

    4 nM (IC50)

    PI3Kβ

    63 nM (IC50)

    PI3Kγ

    38 nM (IC50)

    mTOR

     

    Autophagy

     

    体外研究
    (In Vitro)

    BGT226 shows significant growth inhibition or signal blockage profiles compared with LY294002 and Rapamycin. BGT226 (10-10000 nM) inhibits FaDu and OECM1 cells growth with IC50s of 23.1±7.4 and 12.5±5.1 nM, respectively[2].
    The expression levels of p-mTOR Ser2481 are decreased in BGT226-treated cell lines (200 nM; 24 hours) and both p-AKT Ser473 and p-mTOR Ser2448 are also decreased in BGT226-treated cell lines[2].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Viability Assay[2]

    Cell Line: FaDu cells; OECM1 cells
    Concentration: 10, 100, 1000, 10000 nM
    Incubation Time:
    Result: Inhibited FaDu and OECM1 cells growth with IC50s of 23.1±7.4 and 12.5±5.1 nM, respectively.

    Western Blot Analysis[2]

    Cell Line: FaDu cells; OECM1 cells
    Concentration: 200 nM
    Incubation Time: 24 hours
    Result: p-mTOR Ser2481 expression levels decreased, and both p-AKT Ser473 and p-mTOR Ser2448 expression levels also decreased.

    体内研究
    (In Vivo)

    BGT226 (2.5 and 5 mg/kg; oral administration for 21 days in male athymic mice) causes 34.7% and 76.1% reduction of the tumor growth on day 21 compared with control[2].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Male athymic mice (strain BALB/cAnN.Cg-Foxn1nu/CrlNarl) with FaDu cell xenografted mouse model[2]
    Dosage: 2.5 and 5 mg/kg
    Administration: Oral administration; 21 days
    Result: Caused 34.7% and 76.1% reduction of the tumor growth.

    Clinical Trial

    分子量

    534.53

    Formula

    C28H25F3N6O2
    CAS 号

    915020-55-2
    运输条件

    Room temperature in continental US; may vary elsewhere.
    储存方式

    Please store the product under the recommended conditions in the Certificate of Analysis.
    参考文献

    • [1]. Markman B, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Ann Oncol. 2012 Sep;23(9):2399-408.

      [2]. Chang KY, et al. Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo. Clin Cancer Res. 2011 Nov 15;17(22):7116-26.

    所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

    螺旋霉素

    发表于由

    螺旋霉素

    有货

    螺旋霉素

    CAS编号 8025-81-8 | 品牌：Jinpan
    Spiramycin

    MSDS

    质检证书(CoA)

    相似产品

    • 分子式 C43H74N2O14
    • 分子量843.06
    • EC号 232-429-6
    • PubChem编号 134687906

    货号 (SKU) 包装规格 是否现货 价格 数量
    S434234-5g 5g 期货 螺旋霉素  
    S434234-1g 1g 期货 螺旋霉素  

    基本信息

    产品名称 螺旋霉素
    英文名称 Spiramycin
    别名 Formacidine
    英文别名 Formacidine
    生化机理 Spiramycin is a 16-membered ring macrolide antibiotic from Streptomyces ambofaciens . It inhibits bacterial protein synthesis at the level of peptidy-tRNA dissociation from ribosomes. It is mainly used against Gram-positive bacteria.

    一般描述

    General Description

    Chemical structure: macrolide

    Application

    Spiramycin is a macrolide antibiotic that is commonly used to treat infections of soft tissues. It has been used to treat bronchopulmonary infections in adults and has been used to study septicemia in mice .

    Other Notes

    Keep container tightly closed in a dry and well-ventilated place.

    General Description

    Chemical structure: macrolide

    Application

    Spiramycin is a macrolide antibiotic that is commonly used to treat infections of soft tissues. It has been used to treat bronchopulmonary infections in adults and has been used to study septicemia in mice .

    Other Notes

    Keep container tightly closed in a dry and well-ventilated place.

    相关属性

    CAS编号 8025-81-8
    比旋光度 81 ° (C=2, 10% AcOH)
    熔点 134-137°C
    溶解性 甲醇：可溶
    储存温度 干燥
    RTECS WG9400000
    分子量 843.06
    分子式 C43H74N2O14
    EC号 232-429-6
    品牌 Jinpan
    PubChem CID 134687906

    Atazanavir-d6(Synonyms: BMS-232632-d6)

    发表于由

    上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

    Atazanavir-d6 (Synonyms: BMS-232632-d6)

    Atazanavir-d6 是 Atazanavir 氘代物。Atazanavir (BMS-232632) 是一种高选择性的 HIV-1蛋白酶抑制剂，用于艾滋病毒感染的研究。Atazanavir 是 CYP3A4 的底物和抑制剂，也是 P-糖蛋白的抑制剂和诱导剂。Atazanavir 也是 SARS-CoV 3CLpro 的抑制剂，IC50 为 3.49 μM。

    Atazanavir-d6(Synonyms: BMS-232632-d6)

    Atazanavir-d6 Chemical Structure

    CAS No. : 1092540-50-5

    规格 是否有货
    100 mg   询价  
    250 mg   询价  
    500 mg   询价  

    * Please select Quantity before adding items.

    生物活性

    Atazanavir-d6 is deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)[2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3].

    体外研究
    (In Vitro)

    Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

    Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
    分子量

    710.89

    Formula

    C38H46D6N6O7
    CAS 号

    1092540-50-5
    运输条件

    Room temperature in continental US; may vary elsewhere.
    储存方式

    Please store the product under the recommended conditions in the Certificate of Analysis.
    参考文献

    • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

      [2]. Havlir DV, et al. Atazanavir: new option for treatment of HIV infection. Clin Infect Dis. 2004 Jun 1;38(11):1599-604.

      [3]. Wood R. Atazanavir: its role in HIV treatment. Expert Rev Anti Infect Ther. 2008 Dec;6(6):785-96.

      [4]. Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212.

    所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

    L-Moses(Synonyms: L-45)

    发表于由

    上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

    L-Moses (Synonyms: L-45)

    L-Moses (L-45) 是第一个有效的选择性 p300/CBP 相关因子 (PCAF) 溴结构域 (Brd) 抑制剂，Kd 为 126 nM。

    L-Moses(Synonyms: L-45)

    L-Moses Chemical Structure

    CAS No. : 2079885-05-3

    规格 价格 是否有货
    5 mg ￥5200 询问价格 & 货期
    10 mg ￥8400 询问价格 & 货期

    * Please select Quantity before adding items.

    生物活性

    L-Moses (L-45) is the first potent, selective, and cell-active p300/CBP-associated factor (PCAF) bromodomain (Brd) inhibitor with a Kd of 126 nM[1].

    IC50 & Target

    Brd

    126 nM (Kd)

    体外研究
    (In Vitro)

    L-Moses (L-45) disrupts PCAF-Brd histone H3.3 interaction in cells using a nanoBRET assay, and a co-crystal structure of L-Moses with the homologous Brd PfGCN5 from Plasmodium falciparum rationalizes the high selectivity for PCAF and GCN5 bromodomains. A structure using highly homologous (64 % identity) Brd from Plasmodium falciparum, PfGCN5, of which L-Moses is also a potent ligand (isothermal titration calorimetry (ITC) KD 280 nM), is successfully obtained (PDB: 5TPX). L-Moses binds in the acetylated lysines (KAc) -binding pocket of PfGCN (blue ribbon and sticks) and makes H-bonds (dotted lines) through the triazole to N1436 and the first of a network of four water molecules (red spheres)[1].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
    体内研究
    (In Vivo)

    L-Moses (L-45) shows no observable cytotoxicity in peripheral blood mononuclear cells (PBMC), good cell-permeability, and metabolic stability in human and mouse liver microsomes, supporting its potential for in vivo use[1].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
    分子量

    360.46

    Formula

    C21H24N6
    CAS 号

    2079885-05-3
    运输条件

    Room temperature in continental US; may vary elsewhere.
    储存方式

    Please store the product under the recommended conditions in the Certificate of Analysis.
    参考文献

    • [1]. Moustakim M, et al. Discovery of a PCAF Bromodomain Chemical Probe. Angew Chem Int Ed Engl. 2017 Jan 16;56(3):827-831.

    所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

    英国Grant OLS200圆周/往复一体式水浴摇床

    发表于由

    【简单介绍】

    英国Grant OLS200圆周/往复一体式水浴摇床，温度范围 0 to 99°C, 温度稳定性 ± 0.1°C，采用技术：集圆周振荡与往复振荡于一体；OLS200 摇床优化了曝气和剪切力设计，具有*的重现性，同时Z大幅度提高了混合效率。?

    【详细说明】

    英国Grant OLS200圆周/往复一体式水浴摇床

    产品简述：       

       英国Grant OLS200圆周/往复一体式水浴摇床,温度范围 0 to 99°C, 温度稳定性 ± 0.1°C，采用技术：集圆周振荡与往复振荡于一体；OLS200 摇床优化了曝气和剪切力设计，具有*的重现性，同时大幅度提高了混合效率。

    产品特点：

    精确数字式温度控制
    温度稳定性： ± 0.1°C
    轻松实现线性/轨道振动模式间的切换
    可调振荡速率与振荡幅度
    温度范围：0° to 99°C *
    标配聚碳酸酯盖子

    结构特色：

    1. *的振荡机制，一台仪器支持往复、圆周两种振荡方式，只需改变振荡托盘的方向即可在两种振荡模式间切换
    2. 强力驱动装置：超静设计，运行平稳，速率范围大
    3. 内置加热装置和温度传感器，应用广泛、易清洗
    4. 单独显示控制温度/振荡速率
    5. 附加冷却系统，可降温至0℃
    6. 设计精良，经久耐用
    7. 可选择不同的托盘，适用不同类型的容器—需要另行订购容量：3 x 1000ml, 6 x 500ml,18 x100ml, 11 x 250ml, 45 x 25ml, 28x 50ml

    技术参数：

    型号名称 OLS200圆周/往复一体式水浴摇床
    水浴槽容积 9L
    温度范围
    °C    		 0-99
    温度稳定性   @ 37°C     °C ±0.1
    温度均一性    @ 37°C    °C ±0.1
    温度设定/显示            °C 数字/3个 LED
    温度显示精确度           °C 0.1
    振荡速率范围   轨道      rpm 20-200
                  线性     行程/min 40 to 360**
    轨道式振动    半径       rpm 9
    线性振动    行程长度     mm 18, 28, 36
    振动速率设定/显示 数字/3-数字 LED
    振动速率显示精确度      行程/min 1
    振荡托盘区                mm 375 x 235
    可浸漠深度     min./max.   mm 0/90
    总功率      120V/230V       kW 1.15/1.5
    工作电压                   V 120 or 230
    安全             过温保护/低液面保护 可调式切断保护

    常规应用：

    1. 基本用途 – 解冻，液体加热/制冷，样品温控
    2. 生命科学 – 微生物学研究，大肠杆菌的测定，组织研究，细胞培养，发酵细菌培养，蛋白前处理，
    3. 生化分析，酶分析
    4. 工业 – 冲洗掉膜上残留的熔化剂，材质检测，腐蚀测定
    5. 生物制药 – 药品包衣的溶解度，溶出度检测，以及冷却实体化
    6. 食品&饮料 – 过敏原的提取，食物消化

    Alflutinib(Synonyms: Furmonertinib; AST2818)

    发表于由

    上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

    Alflutinib (Synonyms: Furmonertinib; AST2818)

    Alflutinib is a potent inhibitor of EGFR. Alflutinib inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Alflutinib has the potential for the research of cancer diseases, especially non-small cell lung cancer (NSCLC).

    Alflutinib(Synonyms: Furmonertinib; AST2818)

    Alflutinib Chemical Structure

    CAS No. : 1869057-83-9

    规格 是否有货
    100 mg   询价  
    250 mg   询价  
    500 mg   询价  

    * Please select Quantity before adding items.

    Alflutinib 的其他形式现货产品:

    Alflutinib mesylate

    生物活性

    Alflutinib is a potent inhibitor of EGFR. Alflutinib inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Alflutinib has the potential for the research of cancer diseases, especially non-small cell lung cancer (NSCLC)[1].

    IC50 & Target[1]

    EGFR

     

    体外研究
    (In Vitro)

    AST2818 is designed to inhibit EGFR active mutations as well as the T790M acquired resistant mutation[1].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
    分子量

    568.59

    Formula

    C28H31F3N8O2
    CAS 号

    1869057-83-9
    运输条件

    Room temperature in continental US; may vary elsewhere.
    储存方式

    Please store the product under the recommended conditions in the Certificate of Analysis.
    参考文献

    • [1]. Y. Shi, et al. P2.03-028 Third Generation EGFR Inhibitor AST2818 (Alflutinib) in NSCLC Patients with EGFR T790M Mutation: A phase1/2 Multi-Center Clinical Trial.

    所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

    上海衡平数字粘度计NDJ-1S

    发表于由

    上海衡平数字粘度计NDJ-1S

  • 品牌 衡平|CNSHP
  • 型号 NDJ-1S
  • 货号 NDJ1S
  • 商品详情

    产品简介：

        NDJ-1S(4S)型数字显示粘度计是传统指针式旋转粘度计的升级换代产品。本仪器采用精良的机械设计、制造工艺和单片机控制技术，LED 数码管显示，测量准确；本粘度计采用简洁的三个按键操作模式，一键选配转子号，一键调整转速，一键读取粘度值，使用极为方便。

        NDJ-1S(4S)型数字显示粘度计具有测量灵敏度高，测试结果可靠，使用操作方便，造型美观大方等特点，是用来测量牛顿液体的粘度和非牛顿液体的表观粘度的理想仪器，可广泛应用于油脂、油漆、塑料、药物、食品、涂料、洗涤剂等各种流体粘度的测量。

     

    产品特点：

    • 取代指针式旋转粘度计

    • 高亮度LED数码管显示

    • 一键选配转子号

    • 一键调整转速

    • 一键读取粘度值

    • 精致铝壳包装

     

    技术参数：

    型号 NDJ-1S
    测量范围 1～1×105mPa.s
    转子规格 标配1-4号转子   （选配0号转子可测低粘度至0.1~10mPa.s）
    转子转速（转/分） 6、12、30、60 
    单次测量自动停止 测量结果稳定后，转子自动停止
    测量精度 ±2%（牛顿液体）
    供电电源 交流220V±10%   50HZ±10%
    工作环境 温度5℃~35℃，相对湿度不大于80%
    外形尺寸(mm) 380×320×390   
    净重(kg) 4.5

    • Fosteabine(Synonyms: 阿糖胞苷烷磷酯; Cytarabine ocfosfate; YNK 01)

    发表于由

    上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

    Fosteabine (Synonyms: 阿糖胞苷烷磷酯; Cytarabine ocfosfate; YNK 01)

    Fosteabine 是一种口服的、阿糖胞苷的前体药物类似物，具有抗脱氧胞苷脱氢酶的活性。

    Fosteabine(Synonyms: 阿糖胞苷烷磷酯; Cytarabine ocfosfate; YNK 01)

    Fosteabine Chemical Structure

    CAS No. : 73532-83-9

    规格 是否有货
    100 mg   询价  
    250 mg   询价  
    500 mg   询价  

    * Please select Quantity before adding items.

    生物活性

    Fosteabine is an oral and prodrug analogue of cytarabine which is resistant to deoxycytidine deaminase.

    分子量

    575.67

    Formula

    C27H50N3O8P
    CAS 号

    73532-83-9
    中文名称

    阿糖胞苷烷磷酯
    运输条件

    Room temperature in continental US; may vary elsewhere.
    储存方式

    Please store the product under the recommended conditions in the Certificate of Analysis.
    参考文献

    • [1]. Maloisel F, et al. Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon alpha-2b for the treatment of chronic myelogenous leukemia patients in chronic phase. Leukemia. 2002 Apr;16(4):573-80.

    所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务